drugset / Trial / NCT03755466
Examination of Efficacy and Safety of Baricitinib in RA Patients
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Baricitinib treatment for 12 months 2. Biologics treatment for 12 months 3. Tofacitinib treatment for 12 months
Timeline
- Start
- 2018-11-21
- Primary completion
- 2023-11-20
- Completion
- 2025-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Baricitinib | Small molecule | — | — |
| Comparator | Tofacitinib | Small molecule | 5 mg | — |